RxDoctor Payments Data

Joe Parker

Adult Health · Alamogordo, NMNPI 1245635622

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 38.4% of the total. That places this record below the midpoint for adult health clinicians in NM, where the typical reported total is $388.

$219in general payments, 2019–2025

Across 10 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$84
  • Nxstage Medical, Inc.$54
  • Otsuka America Pharmaceutical, Inc.$23
  • Bayer$16
  • AstraZeneca$14
  • Akebia Therapeutics Inc$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$219 in reported general payments places this provider in the 40th percentile of 52 adult health providers in New Mexico.

See all adult health providers in New Mexico

Medicare billing

Part B allowed, 2024
$97,574
Medicare patients
492
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide39$133,258
JardianceEmpagliflozin37$57,044
AuryxiaFerric Citrate15$40,432
FarxigaDapagliflozin Propanediol21$19,807
SpsSodium Polystyrene Sulfon/Sorb17$5,076
Sevelamer Carbonate33$4,176
Calcium Acetate15$2,671
Potassium Citrate ErPotassium Citrate16$1,692
Calcitriol40$1,236
Furosemide123$883
Gentamicin Sulfate13$741
Lidocaine-PrilocaineLidocaine/Prilocaine27$512
Losartan Potassium44$512
Lisinopril58$453
Potassium Chloride19$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$84$133,25839 claims
Akebia Therapeutics IncAuryxia$14$40,43215 claims
AstraZenecaFarxiga$14$19,80721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 52 adult health providers in New Mexico.

Other adult health in Alamogordo

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →